Table 1 Study Population Demographics and Outcomes, Anchorage, Alaska 2009–2011 (N = 488 total specimens)
N (%) | Mean (Standard Deviation) | |
|---|---|---|
Age Group | ||
< 25 yrs | 194 (40%) | 29.7 yrs. (9.4 yrs) |
25–29 yrs | 124 (25%) | |
30–34 yrs | 78 (16%) | |
35–39 yrs | 34 (7%) | |
40–44 yrs | 20 (4%) | |
45–49 yrs | 13 (3%) | |
≥ 50 yrs | 25 (5%) | |
Ethnic Group | ||
Eskimo | 238 (49%) | |
Indian | 149 (31%) | |
Aleut | 73 (15%) | |
Mixed | 17 (3%) | |
Non-Native | 9 (2%) | |
Non-specific Native | 2 (0.4%) | |
Tobacco use, ever | 246/484 (51%) | |
Current tobacco user | 225/471 (48%) | |
Number of HPV vaccine doses | ||
0 | 440 (90%) | |
1 | 18 (3.7%) | |
2 | 9 (1.8%) | |
3 | 20 (4.1%) | |
4 | 1 (0.2%) | |
Ectocervical biopsy done | 438 (90%) | |
Endocervical curettage done | 402 (82%) | |
Loop Electrosurgical Excision Procedure done | 42 (8.6%) | |
Cytology Referral Diagnosis | ||
Atypical Squamous Cells of Undetermined Significance | 231 (47%) | |
Low-grade Squamous Intraepithelial Lesion | 162 (33%) | |
High-grade Squamous Intraepithelial Lesion | 46 (9%) | |
Atypical Squamous Cells cannot exclude High-Grade Squamous Intraepithelial cells | 25 (5%) | |
Unknown | 24 (5%) | |
Final Pathology Diagnosis | ||
CIN* 3 | 22 (5%) | |
CIN 2 | 45 (9%) | |
CIN 1 | 184 (38%) | |
Metaplasia/Inflammation | 135 (28%) | |
Other** | 46 (9%) | |
Insufficient/No biopsy | 55 (11%) | |
Number of HPV types in HPV positive specimens | ||
1 | 126 (28%) | 2.6 (SD = 1.57) |
2 | 126 (28%) | Median = 2 |
3 | 94 (21%) | |
4 | 55 (12%) | |
5 | 31 (7%) | |
6+ | 26 (6%) | |
Number of 9-valent HPV vaccine types present | ||
0 | 184 (38%) | 0.88 (SD = 0.87) |
1 | 205 (42%) | |
2 | 76 (16%) | |
3 | 19 (4%) | |
4 | 4 (0.8%) | |